Tech Company Financing Transactions
Raven Biotechnologies Funding Round
Vulcan Capital, Bear Stearns Health Innoventures and FirstMark Capital joined a $48.3 million Series D venture round for Raven Biotechnologies. The round was announced on 10/12/2005.
Transaction Overview
Company Name
Announced On
10/12/2005
Transaction Type
Venture Equity
Amount
$48,300,000
Round
Series D
Investors
Vulcan Capital (Lead Investor) (Michael Kranda)
Proceeds Purpose
This financing demonstrates our investors' confidence in our approach to developing novel antibody therapeutics for life-threatening conditions.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
One Corporate Drive
South San Francisco, CA 94080
USA
South San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Raven's approach creates the optimal starting point for developing a new drug with an increased probability of success in the clinic, within a substantially compressed time frame for drug lead development.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
George Schreiner
Chief Operating Officer
John Whelan
Chief Scientific Officer
Jennie Mather
Vice President
Carolyn Adler
Vice President
Stanford Stewart
VP - Manufacturing
Lucille Chang
Browse more venture capital transactions:
Prev: 10/12/2005: Ophthonix venture capital transaction
Next: 10/14/2005: Hubspan venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs